REG - Renalytix PLC - Q3 Trading Update

RenalytixAnnouncement

10/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250410:nRSJ3932Ea&default-theme=true

RNS Number : 3932E  Renalytix PLC  10 April 2025

Renalytix plc

("Renalytix" or the "Company")

 

Q3 Trading Update

 

20% quarter-on-quarter growth delivered

Achievement of key milestone of 1,000 billable tests processed in a quarter

 

LONDON and NEW YORK, 10 April 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY),
a precision medicine company with lead testing service kidneyintelX.dkd, the
only FDA-approved and Medicare reimbursed prognostic test to support
early-stage risk assessment in chronic kidney disease, announces that Q3
trading has been in-line with expectations delivering 20% quarter-on-quarter
revenue growth.

 

The Company has also reached the key milestone of processing over 1,000
billable tests within the quarter for the first time. The onboarding of a
large New York-based primary care network in September 2024 and increasing
performance with direct to physician sales efforts have supported the
continued growth in testing revenues.

 

James McCullough, CEO of Renalytix, commented: "Billable testing volume paid
by insurance companies, including Medicare, continues to grow and I am very
pleased we have crossed the 1,000 billable testing mark. We remain on track to
meet our full year expectations and expect to expand distribution of
kidneyintelX.dkd with initiatives from both new insurance payors, care
networks and hospital systems this year."

 

For further information, please contact:

 

 Renalytix plc                                             www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                     Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)               Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Brough Ransom / Ben Good

 Oberon Capital (Joint Broker)                             Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                                       Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings                             Mob: 07980 541 893 / 07407 804 654

 

 

About Renalytix (www.renalytix.com (http://www.renalytix.com) )

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTILMFTMTJMBIA